Codelivery Material System of Polymer Microfiber Structures for Synergistic Localized Therapy of Glioblastoma
Source abstract
Abstract
High Resolution Image Download MS PowerPoint Slide Glioblastoma is a highly aggressive brain tumor whose treatment has improved little over the past decade. We report on the synergistic effect of the FDA-approved anti-GBM drug (temozolomide) and inhibitors (acriflavine, PT2385) of hypoxia-inducible factors (HIFs) embedded into coaxial fiber membranes (NanoMesh). In vitro cytotoxicity has been evaluated for various glioma cell lines, and synergistic drug combinations have been identified. Preliminary animal studies with the three-drug-loaded NanoMesh indicate a significant improvement of median survival of >50 days and long-term (>120 days) survival rate of 40%, indicating the potential of this material platform as a translatable local GBM therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanofabrication and Lithography Techniques · 3D Printing in Biomedical Research · Material Properties and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanoelectronics Laboratory, Department of Electrical and Computer Engineering
University of Cincinnati
Hunterian Neurosurgical Laboratory, Department of Neurosurgery, School of Medicine
Johns Hopkins University
Department of Pathology
School of Medicine, Johns Hopkins University
Departments of Oncology, Ophthalmology, and Biomedical Engineering
Department of Biomedical Engineering
Funding
National Cancer Institute
References (44)
Show source-provided references
1. 10.1016/S1470-2045(09)70025-710.1016/S1470-2045(09)70025-7 ↗
2. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
3. 10.1016/j.addr.2021.11395110.1016/j.addr.2021.113951 ↗
4. 10.3171/foc.2006.20.4.310.3171/foc.2006.20.4.3 ↗
5. 10.1038/s41582-022-00621-010.1038/s41582-022-00621-0 ↗
6. 10.1200/JCO.2003.05.06310.1200/JCO.2003.05.063 ↗
7. 10.1093/neuonc/nos27310.1093/neuonc/nos273 ↗
8. 10.1007/s00280005058810.1007/s002800050588 ↗
9. 10.1038/nrd141410.1038/nrd1414 ↗
10. 10.1002/cncr.2439810.1002/cncr.24398 ↗
11. 10.1021/acsomega.5c0036410.1021/acsomega.5c00364 ↗
12. Li K. W. · Clin. Cancer Res. · 2003 · 9 · 3441
13. 10.3390/biom1112187010.3390/biom11121870 ↗
14. 10.3390/cancers1415374310.3390/cancers14153743 ↗
15. 10.1186/s12943-023-01835-610.1186/s12943-023-01835-6 ↗
16. 10.1007/s13346-021-01068-410.1007/s13346-021-01068-4 ↗
17. 10.3390/brainsci1205056710.3390/brainsci12050567 ↗
18. 10.1186/s12885-017-3924-y10.1186/s12885-017-3924-y ↗
19. 10.1007/s11060-005-5531-z10.1007/s11060-005-5531-z ↗
20. 10.3171/2009.11.JNS0816210.3171/2009.11.JNS08162 ↗
21. 10.1021/acs.molpharmaceut.4c0070810.1021/acs.molpharmaceut.4c00708 ↗
22. 10.1007/s13346-023-01456-y10.1007/s13346-023-01456-y ↗
23. 10.1021/acs.accounts.7b0021810.1021/acs.accounts.7b00218 ↗
24. 10.1080/1558372080202218210.1080/15583720802022182 ↗
25. 10.1016/j.colsurfb.2022.11268310.1016/j.colsurfb.2022.112683 ↗
26. 10.1039/D2CP03735A10.1039/D2CP03735A ↗
27. 10.1021/acsengineeringau.3c0004410.1021/acsengineeringau.3c00044 ↗
28. 10.1016/j.ces.2021.11646310.1016/j.ces.2021.116463 ↗
29. 10.1039/D2RA02864F10.1039/D2RA02864F ↗
30. 10.1002/cplu.20190028110.1002/cplu.201900281 ↗
31. 10.1038/s41598-019-54283-y10.1038/s41598-019-54283-y ↗
32. 10.1186/s12915-024-02075-w10.1186/s12915-024-02075-w ↗
33. 10.1186/s12935-025-03823-w10.1186/s12935-025-03823-w ↗
34. 10.3389/fonc.2018.0024910.3389/fonc.2018.00249 ↗
35. 10.1038/s41598-020-72290-210.1038/s41598-020-72290-2 ↗
36. 10.1007/s00018-025-05642-810.1007/s00018-025-05642-8 ↗
37. 10.3390/ijms2514752510.3390/ijms25147525 ↗
38. 10.1039/D4MH01802H10.1039/D4MH01802H ↗
39. 10.1038/s41598-017-14990-w10.1038/s41598-017-14990-w ↗
40. 10.1016/j.ejpb.2021.12.01110.1016/j.ejpb.2021.12.011 ↗
41. 10.1021/acs.molpharmaceut.8b0076610.1021/acs.molpharmaceut.8b00766 ↗
42. 10.1016/j.actbio.2017.02.02910.1016/j.actbio.2017.02.029 ↗
43. 10.1021/am402376c10.1021/am402376c ↗
44. 10.3390/ijms24221631610.3390/ijms242216316 ↗